179 related articles for article (PubMed ID: 34831034)
1. GM101 in Combination with Histone Deacetylase Inhibitor Enhances Anti-Tumor Effects in Desmoplastic Microenvironment.
Chang HG; Choi YH; Hong J; Choi JW; Yoon AR; Yun CO
Cells; 2021 Oct; 10(11):. PubMed ID: 34831034
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumor effect mediated by a paclitaxel-conjugated polymeric micelle-coated oncolytic adenovirus.
Kasala D; Lee SH; Hong JW; Choi JW; Nam K; Chung YH; Kim SW; Yun CO
Biomaterials; 2017 Nov; 145():207-222. PubMed ID: 28869866
[TBL] [Abstract][Full Text] [Related]
3. Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression.
Lee CH; Kasala D; Na Y; Lee MS; Kim SW; Jeong JH; Yun CO
Biomaterials; 2014 Jul; 35(21):5505-16. PubMed ID: 24731708
[TBL] [Abstract][Full Text] [Related]
4. HDAC Inhibitors Enhance Efficacy of the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T in Pancreatic and Triple-Negative Breast Cancer Models.
Rodríguez MDCR; Rodríguez IG; Nattress C; Qureshi A; Halldén G
Viruses; 2022 May; 14(5):. PubMed ID: 35632748
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.
Ingemarsdotter CK; Tookman LA; Browne A; Pirlo K; Cutts R; Chelela C; Khurrum KF; Leung EY; Dowson S; Webber L; Khan I; Ennis D; Syed N; Crook TR; Brenton JD; Lockley M; McNeish IA
Mol Oncol; 2015 Apr; 9(4):791-805. PubMed ID: 25560085
[TBL] [Abstract][Full Text] [Related]
6. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
7. Potent antitumor effect of tumor microenvironment-targeted oncolytic adenovirus against desmoplastic pancreatic cancer.
Li Y; Hong J; Oh JE; Yoon AR; Yun CO
Int J Cancer; 2018 Jan; 142(2):392-413. PubMed ID: 28929492
[TBL] [Abstract][Full Text] [Related]
8. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.
Stauber RH; Knauer SK; Habtemichael N; Bier C; Unruhe B; Weisheit S; Spange S; Nonnenmacher F; Fetz V; Ginter T; Reichardt S; Liebmann C; Schneider G; Krämer OH
Oncotarget; 2012 Jan; 3(1):31-43. PubMed ID: 22289787
[TBL] [Abstract][Full Text] [Related]
9. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
[TBL] [Abstract][Full Text] [Related]
10. Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer.
Yoon AR; Jiao A; Hong J; Kim B; Yun CO
Front Immunol; 2024; 15():1360436. PubMed ID: 38812516
[TBL] [Abstract][Full Text] [Related]
11. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.
Höti N; Chowdhury W; Hsieh JT; Sachs MD; Lupold SE; Rodriguez R
Mol Ther; 2006 Dec; 14(6):768-78. PubMed ID: 16990052
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer.
Amnekar RV; Khan SA; Rashid M; Khade B; Thorat R; Gera P; Shrikhande SV; Smoot DT; Ashktorab H; Gupta S
World J Gastroenterol; 2020 Feb; 26(6):598-613. PubMed ID: 32103870
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems.
Goldsmith ME; Aguila A; Steadman K; Martinez A; Steinberg SM; Alley MC; Waud WR; Bates SE; Fojo T
Mol Cancer Ther; 2007 Feb; 6(2):496-505. PubMed ID: 17308048
[TBL] [Abstract][Full Text] [Related]
15. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
[TBL] [Abstract][Full Text] [Related]
16. Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.
Bieler A; Mantwill K; Dravits T; Bernshausen A; Glockzin G; Köhler-Vargas N; Lage H; Gansbacher B; Holm PS
Hum Gene Ther; 2006 Jan; 17(1):55-70. PubMed ID: 16409125
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells.
Li LX; Zhang YL; Zhou L; Ke ML; Chen JM; Fu X; Ye CL; Wu JX; Liu RY; Huang W
J Transl Med; 2013 Oct; 11():257. PubMed ID: 24124726
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells.
Sachs MD; Ramamurthy M; Poel Hv; Wickham TJ; Lamfers M; Gerritsen W; Chowdhury W; Li Y; Schoenberg MP; Rodriguez R
Cancer Gene Ther; 2004 Jul; 11(7):477-86. PubMed ID: 15118762
[TBL] [Abstract][Full Text] [Related]
19. Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade.
Jung BK; Ko HY; Kang H; Hong J; Ahn HM; Na Y; Kim H; Kim JS; Yun CO
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753544
[TBL] [Abstract][Full Text] [Related]
20. Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells.
Lin Z; Zhang Z; Jiang X; Kou X; Bao Y; Liu H; Sun F; Ling S; Qin N; Jiang L; Yang Y
Oncotarget; 2017 Mar; 8(11):17833-17848. PubMed ID: 28147319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
